Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia.
Department of Hematology, Tenri Hospital, Tenri, Japan.
Y
Y
Maesako
Tenri Institute of Medical Research, Tenri, Japan.
A
A
Okumura
Tenri Institute of Medical Research, Tenri, Japan.
K
K
Takeoka
Tenri Institute of Medical Research, Tenri, Japan.
C
C
Kishimori
Department of Hematology, Tenri Hospital, Tenri, Japan.
K
K
Izumi
Department of Hematology, Tenri Hospital, Tenri, Japan.
Y
Y
Kamoda
Department of Hematology, Tenri Hospital, Tenri, Japan.
F
F
Iioka
Department of Hematology, Tenri Hospital, Tenri, Japan.
T
T
Akasaka
1] Department of Hematology, Tenri Hospital, Tenri, Japan [2] Tenri Institute of Medical Research, Tenri, Japan.
H
H
Ohno
D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D000077547:Crizotinib; D005260:Female; D006410:Hematopoiesis; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D015514:Oncogene Proteins, Fusion / Q000032:analysis / Q000502:physiology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics
D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; C000591371:RANBP2-ALK fusion protein, human; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases